Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Clinical trial NCT06855589 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06855589
- Sponsor
- Charles LeMoyne Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2033-03-01
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.